FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bevacizumab
/ adverse effects
Camptothecin
/ analogs & derivatives
Colorectal Neoplasms
/ drug therapy
Fluorouracil
/ adverse effects
Humans
Leucovorin
/ adverse effects
Organoplatinum Compounds
Panitumumab
/ therapeutic use
Propensity Score
Proto-Oncogene Proteins B-raf
/ genetics
Quality of Life
Bevacizumab
Combination chemotherapy
FOLFOX
FOLFOXIRI
Metastatic colorectal cancer
Panitumumab
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
11
08
2020
accepted:
25
11
2020
pubmed:
19
12
2020
medline:
22
6
2021
entrez:
18
12
2020
Statut:
ppublish
Résumé
Doublets plus anti-epidermal growth factor receptors (EGFRs) are the preferred upfront option for patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC). Initial therapy with FOLFOXIRI-bevacizumab is superior to doublets plus bevacizumab independently from primary tumor sidedness and RAS/BRAF status. No randomized comparison between FOLFOXIRI-bevacizumab versus doublets plus anti-EGFRs is available in left-sided RAS/BRAF wild-type mCRC. We selected patients with left-sided RAS and BRAF wild-type mCRC treated with first-line FOLFOX-panitumumab or FOLFOXIRI-bevacizumab in five randomized trials: Valentino, TRIBE, TRIBE2, STEAM, and CHARTA. A propensity score-based analysis was performed to compare FOLFOXIRI-bevacizumab with FOLFOX-panitumumab. A total of 185 patients received FOLFOX-panitumumab and 132 received FOLFOXIRI-bevacizumab. Median progression-free survival (PFS) and median overall survival (OS) were 13.3 and 33.1 months in the FOLFOXIRI-bevacizumab group compared with 11.4 and 30.3 months in the FOLFOX-panitumumab group (propensity score-adjusted hazard ratio (HR) for PFS, 0.82; 95% confidence interval (CI), 0.64-1.04; p = .11; propensity score-adjusted HR for OS, 0.80; 95% CI, 0.59-1.08; p = .14). No significant differences in overall response rate and disease control rate were observed. A statistically nonsignificant difference in favor of FOLFOXIRI-bevacizumab was observed for OS after secondary resection of metastases. Chemotherapy-related adverse events were more frequent in the FOLFOXIRI-bevacizumab group, with specific regard to grade 3 and 4 neutropenia (48% vs. 26%, adjusted p = .001). Although randomized comparison is lacking, both FOLFOXIRI-bevacizumab and FOLFOX-panitumumab are valuable treatment options in left-sided RAS/BRAF wild-type mCRC. A propensity score-based analysis of five trials was performed to compare FOLFOX-panitumumab versus FOLFOXIRI-bevacizumab in left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC). No significant differences were observed, but FOLFOXIRI-bevacizumab achieved numerically superior survival outcomes versus FOLFOX-panitumumab. Chemotherapy-related adverse events were more frequent in the FOLFOXIRI-bevacizumab group. These observations suggest that although doublet chemotherapy plus anti-EGFRs remains the preferred treatment in patients with left-sided RAS/BRAF wild-type mCRC, FOLFOXIRI-bevacizumab is a valuable option able to provide similar, if not better, outcomes at the price of a moderate increase in toxicity and may be adopted based on patients' preference and potential impact on quality of life.
Sections du résumé
BACKGROUND
Doublets plus anti-epidermal growth factor receptors (EGFRs) are the preferred upfront option for patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC). Initial therapy with FOLFOXIRI-bevacizumab is superior to doublets plus bevacizumab independently from primary tumor sidedness and RAS/BRAF status. No randomized comparison between FOLFOXIRI-bevacizumab versus doublets plus anti-EGFRs is available in left-sided RAS/BRAF wild-type mCRC.
MATERIALS AND METHODS
We selected patients with left-sided RAS and BRAF wild-type mCRC treated with first-line FOLFOX-panitumumab or FOLFOXIRI-bevacizumab in five randomized trials: Valentino, TRIBE, TRIBE2, STEAM, and CHARTA. A propensity score-based analysis was performed to compare FOLFOXIRI-bevacizumab with FOLFOX-panitumumab.
RESULTS
A total of 185 patients received FOLFOX-panitumumab and 132 received FOLFOXIRI-bevacizumab. Median progression-free survival (PFS) and median overall survival (OS) were 13.3 and 33.1 months in the FOLFOXIRI-bevacizumab group compared with 11.4 and 30.3 months in the FOLFOX-panitumumab group (propensity score-adjusted hazard ratio (HR) for PFS, 0.82; 95% confidence interval (CI), 0.64-1.04; p = .11; propensity score-adjusted HR for OS, 0.80; 95% CI, 0.59-1.08; p = .14). No significant differences in overall response rate and disease control rate were observed. A statistically nonsignificant difference in favor of FOLFOXIRI-bevacizumab was observed for OS after secondary resection of metastases. Chemotherapy-related adverse events were more frequent in the FOLFOXIRI-bevacizumab group, with specific regard to grade 3 and 4 neutropenia (48% vs. 26%, adjusted p = .001).
CONCLUSION
Although randomized comparison is lacking, both FOLFOXIRI-bevacizumab and FOLFOX-panitumumab are valuable treatment options in left-sided RAS/BRAF wild-type mCRC.
IMPLICATIONS FOR PRACTICE
A propensity score-based analysis of five trials was performed to compare FOLFOX-panitumumab versus FOLFOXIRI-bevacizumab in left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC). No significant differences were observed, but FOLFOXIRI-bevacizumab achieved numerically superior survival outcomes versus FOLFOX-panitumumab. Chemotherapy-related adverse events were more frequent in the FOLFOXIRI-bevacizumab group. These observations suggest that although doublet chemotherapy plus anti-EGFRs remains the preferred treatment in patients with left-sided RAS/BRAF wild-type mCRC, FOLFOXIRI-bevacizumab is a valuable option able to provide similar, if not better, outcomes at the price of a moderate increase in toxicity and may be adopted based on patients' preference and potential impact on quality of life.
Identifiants
pubmed: 33336844
doi: 10.1002/onco.13642
pmc: PMC8018298
doi:
Substances chimiques
Organoplatinum Compounds
0
Bevacizumab
2S9ZZM9Q9V
Panitumumab
6A901E312A
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Camptothecin
XT3Z54Z28A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
302-309Informations de copyright
© 2020 AlphaMed Press.
Références
Eur J Cancer. 2017 Jan;70:87-98
pubmed: 27907852
Eur J Cancer. 2020 Aug;135:230-239
pubmed: 32623288
Ann Oncol. 2018 Jan 1;29(1):44-70
pubmed: 29155929
J Clin Oncol. 2019 Nov 20;37(33):3099-3110
pubmed: 31539295
J Clin Oncol. 2020 Aug 20;:JCO2001225
pubmed: 32816630
J Natl Cancer Inst. 2015 Feb 24;107(3):
pubmed: 25713148
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
J Clin Oncol. 2019 Jan 1;37(1):22-32
pubmed: 30388045
Br J Cancer. 2018 Dec;119(12):1451-1455
pubmed: 30487637
Lancet Oncol. 2020 Apr;21(4):497-507
pubmed: 32164906
JAMA Oncol. 2019 Jul 3;:
pubmed: 31268481
Br J Cancer. 2018 Apr;118(7):955-965
pubmed: 29531324
Oncologist. 2019 Jul;24(7):921-932
pubmed: 30552157
Ann Oncol. 2019 Dec 1;30(12):1969-1977
pubmed: 31573612
Stat Med. 2014 Mar 30;33(7):1242-58
pubmed: 24122911
Ann Oncol. 2018 Apr 20;29(7):1528-1534
pubmed: 29873679
Ann Oncol. 2017 Sep 1;28(9):2128-2134
pubmed: 28911067
Eur J Cancer. 2017 Mar;73:74-84
pubmed: 27986363
Ann Oncol. 2014 Oct;25(10):1995-2001
pubmed: 25057166
Ann Oncol. 2017 Aug 1;28(8):1713-1729
pubmed: 28407110
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
ESMO Open. 2018 Jul 9;3(4):e000403
pubmed: 30018814
Ann Oncol. 2017 Dec 1;28(12):3009-3014
pubmed: 29045518